<SEC-DOCUMENT>0001651308-26-000012.txt : 20260515
<SEC-HEADER>0001651308-26-000012.hdr.sgml : 20260515
<ACCEPTANCE-DATETIME>20260515160807
ACCESSION NUMBER:		0001651308-26-000012
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20260513
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260515
DATE AS OF CHANGE:		20260515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BeOne Medicines Ltd.
		CENTRAL INDEX KEY:			0001651308
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				981209416
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37686
		FILM NUMBER:		26987264

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		C/O BEONE MEDICINES I GMBH
		STREET 2:		AESCHENGRABEN 27, 21ST FLOOR
		CITY:			BASEL
		PROVINCE COUNTRY:   	V8
		ZIP:			4051
		BUSINESS PHONE:		41-616851900

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		C/O BEONE MEDICINES I GMBH
		STREET 2:		AESCHENGRABEN 27, 21ST FLOOR
		CITY:			BASEL
		PROVINCE COUNTRY:   	V8
		ZIP:			4051

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BeiGene, Ltd.
		DATE OF NAME CHANGE:	20150819
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bgne-20260513.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e282a-e11d-756f-9ce2-f89d7f33d68e,g:0e7c755e-b304-48e0-8138-b25481930a43,d:167998755fc64d2baeed22faf398df57-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bgne-20260513</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001651308</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bgne-20260513.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-05-13</xbrli:startDate><xbrli:endDate>2026-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-14</xbrli:startDate><xbrli:endDate>2026-04-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i167998755fc64d2baeed22faf398df57_1"></div><div style="min-height:18pt;width:100%"><div style="margin-bottom:0.08pt"><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:0.08pt;padding-left:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.093%"><tr><td style="width:0.1%"/><td style="width:1.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:97.138%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.343%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:1pt"><td colspan="9" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">_____________________</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:100%">Form <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">______________________</span></div><div style="margin-top:9.9pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">CURRENT REPORT</span></div><div style="margin-top:5.4pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date of Report (Date of earliest event Reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May 13, 2026</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">BEONE MEDICINES LTD.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(Exact Name of Registrant as Specified in Charter)</span></div><div><span><br/></span></div><div style="margin-bottom:0.08pt;padding-left:12.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.354%"><tr><td style="width:1.0%"/><td style="width:3.764%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.764%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.764%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.770%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.92pt;padding-right:0.92pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-4">Switzerland</ix:nonNumeric></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.4pt;padding-right:1.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37686</ix:nonNumeric></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.4pt;padding-right:2.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">98-1209416</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.37pt;padding-right:3.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.4pt;padding-right:2.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.4pt;padding-right:3.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></div></td></tr></table></div><div style="margin-top:4.5pt;padding-left:2pt;padding-right:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">c/o BeOne Medicines I GmbH<br/><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">Aeschengraben 27</ix:nonNumeric></span></div><div style="margin-top:0.9pt;padding-left:2pt;padding-right:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Basel</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-9">4051</ix:nonNumeric><br/><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-10">Switzerland</ix:nonNumeric></span></div><div style="margin-top:0.9pt;padding-left:2pt;padding-right:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="margin-top:0.9pt;padding-left:2pt;padding-right:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">+41 <ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">61</ix:nonNumeric> <ix:nonNumeric contextRef="c-2" name="dei:LocalPhoneNumber" id="f-12">685 19 00</ix:nonNumeric></span></div><div style="margin-top:0.9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant's telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Former name or former address, if changed since last report)</span></div><div style="margin-bottom:0.08pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:5.4pt;padding-left:2pt;padding-right:2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="padding-left:2pt;padding-right:2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="padding-left:2pt;padding-right:2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="padding-left:2pt;padding-right:2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric> </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span><br/></span></div><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><span><br/></span></div><div style="margin-bottom:0.08pt;padding-left:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.223%"><tr><td style="width:1.0%"/><td style="width:2.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.702%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.783%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></div></td><td colspan="9" style="padding:0 1pt"/><td colspan="9" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.4pt;padding-right:1.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></div></td><td colspan="9" style="padding:0 1pt"/><td colspan="9" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.4pt;padding-right:1.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share</ix:nonNumeric></span></div></td><td colspan="9" style="padding:0 1pt"/><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.95pt;padding-right:0.95pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">ONC</ix:nonNumeric></span></div></td><td colspan="9" style="padding:0 1pt"/><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.4pt;padding-right:1.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Ordinary Shares, par value $0.0001 per share*</span></div></td><td colspan="9" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.4pt;padding-right:1.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">06160</span></div></td><td colspan="9" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.4pt;padding-right:1.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">The Stock Exchange of Hong Kong Limited</span></div></td></tr></table></div><div style="margin-top:8.1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">*Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited.</span></div><div style="margin-top:5.4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2). </span><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span></div><div style="margin-top:5.4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="margin-top:5.4pt"><span><br/></span></div><div style="margin-bottom:0.08pt"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div style="margin-bottom:0.08pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Item 8.01. Other Events.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 13, 2026, BeOne Medicines Ltd. announced that BEQALZI&#8482; (sonrotoclax) has received accelerated approval from the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory mantle cell lymphoma, after at least two lines of systemic therapy, including a Bruton&#8217;s tyrosine kinase inhibitor. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibits</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.968%"><tr><td style="width:1.0%"/><td style="width:10.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.741%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.475%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit No.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Description</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">99.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Press release titled &#8220;BeOne Medicines&#8217; BEQALZI&#8482; (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma&#8221;, issued by BeOne Medicines Ltd. on May 13, 2026</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">104</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div style="margin-bottom:0.08pt"><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">  </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.734%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.968%"><tr><td style="width:1.0%"/><td style="width:10.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.741%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.475%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit No.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Description</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">99.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="a20260515formxsonroapprova.htm">Press release titled &#8220;BeOne Medicines&#8217; BEQALZI&#8482; (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma&#8221;, issued by BeOne Medicines Ltd. on May 13, 2026</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">104</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div style="margin-bottom:0.08pt"><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div style="margin-bottom:0.08pt;padding-left:12.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.963%"><tr><td style="width:0.1%"/><td style="width:1.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.920%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.789%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.9pt;padding-right:1.85pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.9pt;padding-right:4.9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">BEONE MEDICINES LTD.</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.9pt;padding-right:1.85pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.9pt;padding-right:1.9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.9pt;padding-right:1.9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.9pt;padding-right:1.85pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.9pt;padding-right:1.9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.9pt;padding-right:1.9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.9pt;padding-right:1.85pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 15, 2026</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.9pt;padding-right:1.9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:&#160;</span></div></td><td colspan="9" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.9pt;padding-right:1.9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Chan Lee&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.9pt;padding-right:1.85pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.9pt;padding-right:1.9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></div></td><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.9pt;padding-right:1.9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chan Lee</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.9pt;padding-right:1.85pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.9pt;padding-right:1.9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.9pt;padding-right:1.9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel</span></div></td></tr></table></div><div style="margin-top:4.5pt"><span><br/></span></div><div><span><br/></span></div><div style="margin-top:10.8pt"><span><br/></span></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a20260515formxsonroapprova.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i6fd82e1409f04f10b2e458c4a507acb2_1"></div><div style="min-height:72pt;width:100%"><div style="padding-right:5.5pt;text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><font><br></font></div><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:29px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">BeOne Medicines&#8217; BEQALZI</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R&#47;R Mantle Cell Lymphoma</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potential to improve efficacy, tolerability, and convenience versus others in the class </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approval of BEQALZI marks the first new BCL2 inhibitor approved in a decade in the U.S. and the only BCL2 inhibitor approved in MCL, aiming to set a new standard of innovation </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SAN CARLOS, Calif. &#8211; May 13, 2026 &#8211; BeOne Medicines Ltd. (&#8220;BeOne&#8221;) (Nasdaq&#58; ONC&#59; HKEX&#58; 06160&#59; SSE&#58; 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(bee-KAHL-zee&#59; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R&#47;R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton&#8217;s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition&#8212;with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, and convenience over others in the class. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Michael Wang, M.D., Global Principal Investigator, the Puddin Clarke Endowed Professor, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, said&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;The data supporting the approval of sonrotoclax in the U.S. confirm its role as a foundational therapy for mantle cell lymphoma in the post-BTK inhibitor setting, and demonstrate that it can deliver robust disease control when treatment choices are limited and outcomes are poor. From a clinical perspective, this provides physicians with an important new option grounded in both efficacy and tolerability, fundamentally changing how we think about sequencing therapy in this disease.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Data supporting approval</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accelerated approval of BEQALZI is supported by efficacy and safety data from the Phase 1&#47;2 study, BGB-11417-201 (NCT05471843), which was presented at the&#160;67</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> American Society of Hematology (ASH) Annual Meeting &#38; Exposition. The study included an independent review of efficacy data and demonstrated&#58; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Overall response rate (ORR)&#58; 52% (95% CI, 42-62) </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Complete response (CR) rate&#58; 16% (95% CI, 9.1-24.0)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Median time to response (TTR)&#58; 1.9 months</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Median duration of response (DOR)&#58; 15.8 months (95% CI, 7.4 months-NE) at a median response follow-up of 11.9 months (has yet to reach full maturity)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Safety&#58; treatment with sonrotoclax monotherapy was generally well tolerated </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Continued approval for this indication is contingent upon confirmation of clinical benefit in the confirmatory CELESTIAL-RRMCL trial (NCT06742996), which is underway. The U.S. FDA granted Breakthrough Therapy Designation (BTD) for sonrotoclax in this indication, as well as Fast Track Designation and Orphan Drug Designation. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;BeOne is leading the advancement and enhancement of BCL2 inhibition to revolutionize how we treat patients living with B cell malignancies. Today&#8217;s approval of BEQALZI represents critical progress for patients with mantle cell lymphoma and reinforces our strategy of building foundational medicines designed to raise the standard of care in B-cell malignancies.&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-right:5.5pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">A new BCL2 option for a challenging R&#47;R MCL post&#8211;BTK inhibitor setting</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCL is a rare and often aggressive subtype of non-Hodgkin lymphoma. In the United States, approximately 3,300 new cases of MCL are diagnosed each year.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> While many patients respond to initial therapy, relapse is common, and outcomes after progression can be poor, particularly after prior treatment with a BTK inhibitor. The accelerated approval of BEQALZI introduces a new targeted mechanism to the MCL treatment landscape and reinforces the importance of expanding therapeutic choices for patients as the disease evolves.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Meghan Gutierrez, Chief Executive Officer, Lymphoma Research Foundation, said&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;For people living with relapsed or refractory mantle cell lymphoma, each progression can bring uncertainty and questions regarding remaining treatment options. The FDA approval of sonrotoclax represents significant progress for the U.S. mantle cell lymphoma community, offering renewed hope for patients and families who have exhausted other available therapies. Advances like this underscore why continued research and innovation in this disease remain so critical.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Additional regulatory and development updates </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">BEQALZI is also approved in China for the treatment of R&#47;R MCL, as well as adult patients with chronic lymphocytic leukemia (CLL)&#47;small lymphocytic lymphoma (SLL) who have previously received at least one systemic therapy, including a BTK inhibitor. Data from the Phase 1&#47;2 study of sonrotoclax in R&#47;R MCL is also under review by the European Medicines Agency and other regulatory agencies.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. FDA also granted sonrotoclax Fast Track Designation for Waldenstr&#246;m macroglobulinemia (WM), as well as Orphan Drug Designation for the treatment of adult patients with WM, multiple myeloma, acute myeloid leukemia, and myelodysplastic syndrome.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, sonrotoclax is currently being studied in combination with other therapeutics, including zanubrutinib, as a potential treatment for CLL, with updated data expected to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">About BEQALZI</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> (sonrotoclax) </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">BEQALZI</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (sonrotoclax) is a foundational, next-generation and potentially best-in-class B-cell lymphoma 2 (BCL2) inhibitor with a unique pharmacokinetic and pharmacodynamic profile. Preclinical and clinical studies in early drug development have shown that sonrotoclax is a highly potent and specific BCL2 inhibitor with a short half-life and no drug accumulation. Sonrotoclax has shown promising clinical activity across a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL), and is in development as a monotherapy and in combination with other therapeutics, including zanubrutinib. To date, more than 2,200 patients have been enrolled across the broad sonrotoclax global development program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">INDICATION</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">BEQALZI&#8482; (sonrotoclax) is a BCL-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory (R&#47;R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton&#8217;s tyrosine kinase (BTK) inhibitor.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">IMPORTANT SAFETY INFORMATION</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONTRAINDICATIONS </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">BEQALZI is contraindicated with strong CYP3A inhibitors at initiation and during the ramp-up phase due to the potential for an increased risk of tumor lysis syndrome (TLS).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-right:5.5pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">WARNINGS &#38; PRECAUTIONS</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Tumor Lysis Syndrome (TLS)&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> BEQALZI can cause rapid tumor reduction and changes in blood chemistries consistent with TLS, which may be serious or life-threatening and require prompt management. TLS may occur as early as 4 hours after the first dose, with dose increases, or upon reinitiation following treatment interruption. Laboratory or clinical TLS occurred in 7% of patients who followed the recommended dose ramp-up. Assess all patients for TLS risk and initiate prophylaxis, including adequate hydration and antihyperuricemics. For patients at high risk of TLS, consider hospitalization with intravenous hydration and employ frequent monitoring. Monitor blood chemistries closely and manage abnormalities promptly. Interrupt BEQALZI for TLS&#59; upon reinitiation, follow dose modification guidance in the Prescribing Information.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Serious Infections&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> BEQALZI can cause fatal or serious infections. Serious infections occurred in 14% of patients&#59; Grade 3-4 occurred in 17% (fatal&#58; 2.6%). The most common Grade 3 or greater infection was pneumonia (10%). Monitor for signs and symptoms of infection and treat appropriately. Consider prophylactic antimicrobials and immunoglobulins. Interrupt, reduce dose, or permanently discontinue BEQALZI based on severity.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Neutropenia&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">BEQALZI can cause serious or severe cytopenias, including neutropenia. Grade 3 or 4 decreases in neutrophils occurred in 18% of patients (Grade 4&#58; 6%)&#59; febrile neutropenia occurred in 1.7% of all patients. Monitor complete blood counts throughout treatment. Interrupt treatment, reduce the dose, or permanently discontinue BEQALZI based on severity. </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Embryo-Fetal Toxicity&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">BEQALZI can cause fetal harm when administered to pregnant women. Advise patients of the potential risk to a fetus. Verify pregnancy status prior to initiation. Advise females to use effective contraception and males with female partners of reproductive potential to use effective contraception during treatment and for 1 week after the last dose.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">ADVERSE REACTIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The most common adverse reactions (&#8805;15%) are pneumonia (16%) and fatigue (16%). The most common Grade 3-4 laboratory abnormalities (&#8805;15%) are decreases in lymphocytes (29%) and neutrophils (18%).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">DRUG INTERACTIONS</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Strong or Moderate CYP3A Inhibitors&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Concomitant use increases BEQALZI exposure. Avoid use of strong CYP3A inhibitors during BEQALZI initiation and ramp-up. Avoid use of moderate CYP3A inhibitors at the 1 mg and 2 mg doses&#59; for all other doses, reduce the BEQALZI dose with concomitant use. See approved labeling for dose modifications.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Strong or Moderate CYP3A Inducers&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Concomitant use decreases BEQALZI exposure. Avoid use.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">SPECIAL POPULATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Lactation&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Advise women not to breastfeed during treatment with BEQALZI and for 1 week after the last dose.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To report SUSPECTED ADVERSE REACTIONS, contact BeOne Medicines at 1-877-828-5596 or FDA at 1-800-FDA-1088 or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.fda.gov&#47;medwatch</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Please see full&#160;U.S. Prescribing Information.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">About BeOne</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-right:5.5pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statement </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential benefits of sonrotoclax&#59; BeOne&#8217;s expectations regarding sonrotoclax&#8217;s clinical development, regulatory milestones, submissions and approvals&#59; and BeOne&#8217;s plans, commitments, aspirations and goals under the caption &#8220;About BeOne.&#8221; Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne&#8217;s ability to demonstrate the efficacy and safety of its drug candidates&#59; the clinical results for its drug candidates, which may not support further development or marketing approval&#59; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval&#59; BeOne&#8217;s ability to achieve commercial success for its marketed medicines and drug candidates, if approved&#59; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology&#59; BeOne&#8217;s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services&#59; BeOne&#8217;s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products&#59; BeOne&#8217;s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability&#59; and those risks more fully discussed in the section entitled &#8220;Risk Factors&#8221; in BeOne&#8217;s most recent periodic report, as well as discussions of potential risks, uncertainties, and other important factors in BeOne&#8217;s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.</font></div><div><font><br></font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.903%"><tr><td style="width:1.0%"></td><td style="width:41.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;padding-left:0.02pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">Investor Contact</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;padding-left:0.02pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">Media Contact</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;padding-left:0.02pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Liza Heapes</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;padding-left:0.02pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Kyle Blankenship</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;padding-left:0.02pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">+1 857-302-5663</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;padding-left:0.02pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">+ 1 667-351-5176</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;padding-left:0.02pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">ir&#64;beonemed.com</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">media&#64;beonemed.com</font></div></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To access BeOne media resources, please visit our</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> Newsroom</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:-2.98pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>bgne-20260513.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e282a-e11d-756f-9ce2-f89d7f33d68e,g:0e7c755e-b304-48e0-8138-b25481930a43-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bgne="http://www.beigene.com/20260513" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.beigene.com/20260513">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bgne-20260513_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bgne-20260513_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.beigene.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>bgne-20260513_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e282a-e11d-756f-9ce2-f89d7f33d68e,g:0e7c755e-b304-48e0-8138-b25481930a43-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019e282a-e11d-7966-a353-2d689ef601d3_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_019e282a-e11d-730c-b44b-8c817feee9df_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019e282a-e11d-7b8c-944d-5db92037c85e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019e282a-e11d-7843-aab5-ab32d83c8c2d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019e282a-e11d-7789-8056-a95793628af0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_019e282a-e11d-78fd-ba2a-c420bddc0ac3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019e282a-e11d-79e0-8836-46fffe4de570_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019e282a-e11d-7c8a-bcab-5f4093c803cd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_019e282a-e11d-7407-9e38-cf5786f6d144_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019e282a-e11d-788f-a8cd-da5ab9bd9f8f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_019e282a-e11d-711f-877f-2e8c63dfbe58_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019e282a-e11d-7c2f-9cc9-7b7b882866dc_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019e282a-e11d-7a53-9dc8-056c856662ec_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019e282a-e11d-714f-a9e9-9353750c23da_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019e282a-e11d-7dc5-b1d8-c20621e5d478_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019e282a-e11d-7d44-bbb4-3a5a2bebf612_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019e282a-e11d-7694-b517-0eb8e250c278_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019e282a-e11d-70ff-8988-b80866bb628a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019e282a-e11d-7213-8222-1ace5e764101_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_019e282a-e11d-787f-8280-786d12b12045_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019e282a-e11d-74c6-9d53-24133eea9031_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019e282a-e11d-7df7-b2d1-ed5b6f334dac_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>bgne-20260513_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e282a-e11d-756f-9ce2-f89d7f33d68e,g:0e7c755e-b304-48e0-8138-b25481930a43-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.beigene.com/role/Cover" xlink:type="simple" xlink:href="bgne-20260513.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019e282a-e11d-7459-b2dc-5f2cba2d80e8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_DocumentType_019e282a-e11d-7459-b2dc-5f2cba2d80e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019e282a-e11d-704b-8593-01791518ae1c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_DocumentPeriodEndDate_019e282a-e11d-704b-8593-01791518ae1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019e282a-e11d-7d8e-866b-33ea3d99982f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_EntityRegistrantName_019e282a-e11d-7d8e-866b-33ea3d99982f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019e282a-e11d-7da8-9a64-e063218b969f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019e282a-e11d-7da8-9a64-e063218b969f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019e282a-e11d-7b34-995e-0cf7fc95c0d9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_EntityAddressAddressLine1_019e282a-e11d-7b34-995e-0cf7fc95c0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019e282a-e11d-7d2b-9caf-de1661f417d9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_EntityAddressCityOrTown_019e282a-e11d-7d2b-9caf-de1661f417d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019e282a-e11d-7a56-8345-510a33378b0d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_EntityAddressPostalZipCode_019e282a-e11d-7a56-8345-510a33378b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_019e282a-e11d-7833-9187-44cc4add83db" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_EntityAddressCountry_019e282a-e11d-7833-9187-44cc4add83db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_019e282a-e11d-7be9-a502-d5e35cb658b9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_WrittenCommunications_019e282a-e11d-7be9-a502-d5e35cb658b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_019e282a-e11d-77b9-b48b-c60a4d157ab4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_SolicitingMaterial_019e282a-e11d-77b9-b48b-c60a4d157ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019e282a-e11d-7256-83ed-ce51530d172d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_CityAreaCode_019e282a-e11d-7256-83ed-ce51530d172d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019e282a-e11d-755f-b0e6-895f780b49e7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_LocalPhoneNumber_019e282a-e11d-755f-b0e6-895f780b49e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_019e282a-e11d-720d-8033-71933d2a61a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_PreCommencementTenderOffer_019e282a-e11d-720d-8033-71933d2a61a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_019e282a-e11d-7185-b0e3-e006955e180a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_019e282a-e11d-7185-b0e3-e006955e180a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019e282a-e11d-78df-80a1-05010fe9857e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_Security12bTitle_019e282a-e11d-78df-80a1-05010fe9857e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019e282a-e11d-78ad-bbb2-90490299dd03" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_TradingSymbol_019e282a-e11d-78ad-bbb2-90490299dd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019e282a-e11d-78d4-8edc-83e2cbc2dd22" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_SecurityExchangeName_019e282a-e11d-78d4-8edc-83e2cbc2dd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019e282a-e11d-736f-bc1f-1ab9319d7450" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_EntityEmergingGrowthCompany_019e282a-e11d-736f-bc1f-1ab9319d7450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019e282a-e11d-7098-9aa4-85b682a5cb0f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_EntityCentralIndexKey_019e282a-e11d-7098-9aa4-85b682a5cb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019e282a-e11d-7ddf-a783-51fc235b4a73" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_AmendmentFlag_019e282a-e11d-7ddf-a783-51fc235b4a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019e282a-e11d-771f-be38-7062bf2eeadc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_EntityTaxIdentificationNumber_019e282a-e11d-771f-be38-7062bf2eeadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019e282a-e11d-760c-9f22-cd7ea4519df5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e282a-e11d-7e6e-b7d5-0d15a294c4bf" xlink:to="loc_dei_EntityFileNumber_019e282a-e11d-760c-9f22-cd7ea4519df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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M4[TFZ-2^YG=8%P6=EIM+,M2\0$;R>&GRV9#R6;DK1'4EYE>(2%>7./#,KT4
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M/5GX4I!LCQ\+4$%Q-)-O:J>$^N"S3S* CFW_V.@7LPQP5@"RNY?+UL2BS]3
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M:[%^SQA S";N$NCST#]$U>9^21YW1IF#^G"_!&6\S?U ''ALGFV*/7^!,J'
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M@;ENX08 J,>[, H[!V2I?MQ? D"-%L&)*:+ZMIM%X\I'1-.&M:)MQ_^(]E!
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M#_T_4VN_\\WS_TS]_R)EUPS=?^-#$U-^'9[J//_?^/-R7LY+(E&4_P5T_D2
0%*R,8@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 13, 2026</div></th>
<th class="th"><div>Apr. 14, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 13,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BEONE MEDICINES LTD.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">V8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Aeschengraben 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">685 19 00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ONC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001651308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1209416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="bgne-20260513.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="bgne-20260513.htm">bgne-20260513.htm</File>
    <File>bgne-20260513.xsd</File>
    <File>bgne-20260513_lab.xml</File>
    <File>bgne-20260513_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bgne-20260513.htm": {
   "nsprefix": "bgne",
   "nsuri": "http://www.beigene.com/20260513",
   "dts": {
    "inline": {
     "local": [
      "bgne-20260513.htm"
     ]
    },
    "schema": {
     "local": [
      "bgne-20260513.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "bgne-20260513_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bgne-20260513_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.beigene.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20260513.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20260513.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001651308-26-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001651308-26-000012-xbrl.zip
M4$L#!!0    (  *!KUQ/ZN%AP1D  &60   >    83(P,C8P-3$U9F]R;7AS
M;VYR;V%P<')O=F$N:'1M[3UI<]LXEM_W5V"32MJNE=22+,M7.E6R["2N]K6V
M>S*S7Z8@$A(Q)@DV0%I6__I][P&\)-FQTTGL))JJ2<L\<+S[PN.;((W"MV\"
MP?VW__7FOYM-=J"\+!)QRCPM>"I\EAD93]A'7YAKUFRZIX8JF6DY"5+6;7?[
M[*/2U_*&V_NI3$/Q-A_GS:_V[S>_TB1O1LJ?O7WCRQLF_=]>R/[8W^Z*3J^]
M,V[WQIWVJ"MZF]M>CV^VM[@WZOZ[\P)>A<?M.R:=A>*W%Y&,FX' ^7>WNDFZ
M-Y5^&NQVVNU7+VK/)=SW8?5-6NKN9FL3GDW%;=KDH9S$NW09WABK.(65:9C)
M_K03+DQ[QZOY;4^%2N^^;-/_]O!.<\PC&<YV?[F2D3#L5$S9A8IX_$O#""W'
M]ADC_Q*P=E@:_3EU^X(A0AF+?)^=+F[N\#:0(YFRG9U6I[Y8^N>.C= _,IHP
M'J8 \XA/Q+_;O/6?9/*"&>TM7++;<1-W=Y+;O8CK"<!\I-)41;L(QANA4^GQ
MT,&#0&-OY]CH]9+;%P]<WA((>T \0G][$.^+LUBP$^%+#^Z9UR^WNYVM/;9_
M^+^#X_\[RE?^I1;5)YK\U*KV$F5D*A70G0AY*F_$7JJ2W>9&:PDJ1MP('.#%
M6UA[;[N[]Z77_$! LC6C8JU2Y87\=IT-DD2K&Q HHQG[HW798N\.!HP;]DYJ
MDS(>^^PL#F=L?WC<94<QD;G2; S_OWC]LK>U=\%.> R2A U%&++C690$L+Q'
M4])SH#\:;%>F,)%7 V1O.45:TF/2, X R6*?(RWPT )+%L "&0TK!Q CU"8D
MOS5+5"IB;T80!L(0'I"/3&<--I5I8.^F$L9*%9,1H8B)\1CHR8-G4A4*S4<R
MI#=P"$_%-R*6,*1@0'@F,TRE ?R =3#XP0#;QK"? 2^6H@%T:IR+!P:"\MH0
M',9$US',.X<EGC," (P#SCSNBQQXQ!@(9OQ#%?RP_.63X3'@1$:HGP%[1@ ;
MT80FA2&X]G%A,HYAC4@OBSAY).3_DYE4CF=?4R0O!_3EX)0-!Q?'9Y<--H2U
MC%N,Q')G#V3"C'4V&M8,R2_.B7!VG/HMMH9WN^T]NDF_.WOK;.V4&Y__^?KE
MYO8>.SL=PH^=/?;A]\-_VDOM?J??MA<O+P_MM?[V=G=C<QU@SR:A&B$!Q B%
MR0RX(TIX3(SC<^2Y&-C5$XA/GI88?J>43V@^T-F$#7Q H32IMFA: \&XS@(0
MC1,-$@]>YIXGD _I=TYT@/&53GJT3OKJ\RZGX+61$,W?!Q^.FW\)8<FIJAP;
M<X*] 6P,;#<1L7!$41<##9+P2$XI2GFRUX'7N9^%*4O@#;A@K(!'Y"0&" =>
MT&*LN0?OS]B:4ZKK(+%(JWJH54.G5=D:R!9<U1@U"%!N*#@(LW2J6$@<!9.9
MF4E%)#U<AN8)T+R,O3!#>QMVLZ^S5,7.> *!.-- +<"4US(&4F!K^U>_KY?[
M:17R<PID7Z@Q('$1!QQ5377_T@W<W:,=SBFZ1EW+(9=QE@1<1YR8%%8,'#26
ML.>_KP'A6;U,_[4>I #K O4YR>'EW',BO8"+D'WD\:3!3EH'K09[;R7@N0;L
MRP1^'0%T8'T33G2*$#G/T MCPQ!THV"'L:^F@-QS0((P!A\Z$ G7!17GIAT!
M^V0F0OC=8%<H.V.))@=@ I^[$K= +"<';!#[<!689(BDHL% 1 L!Z(!+WTKL
M9P+5Y;+!Z27<(/ _9R9+$@72$[4Z7.,5*Z,B,VH6 Y DF!L1D\#U&@@6[>HY
M4]%Q*0F.I2SOQ@.IGC:!.RLV!Q@6N!I+_;Z(5$RZ2EBE!MZHQV.X'B)R8/H1
M )+YT@AD=%A9"BMBTT#$%6'E!4IZ #VN!4B42))F@]%5EH(*=3<2A9+AG581
M;,8#P*%"80G@.B'^%DA>8!0C?"0(#>#RF0&5SV,G^V!9P-  2]@O&48J(6$Z
MT0@9:T2!SQH4[&Y-KQK'CQ&&N&8>@C4&]!]/$#.!FK(I0D#&UXR/8-T IC\S
M$ H.;P1L@BFLT$&CY<R.[\ 06RX #N;H,Z?-9[+HY?R%C+74@JJ8[8 CMRWK
MH-8(PO"Q )%#S#E&:B2A%B!Y=TB+=F$WF0_$LO]^O]GI]#I;S6Z[ [;E\*J]
MV=OJ;/<V0)E. Q"?I. 2+8RPEAT9A:]?@I&YU]_Z^H;<,@A]IB&7!D]D2[%!
M!"^BS+E4GA16&7P0$2@<LL'7!I<?UD$IQ!G@^$0(HM37+S= #QS>YGMMD4(A
MM#F[A200_/9%(N ?V)(6-Q*%QK@D!Z*!.3'X*1V3!R%#,4YW-_KU$*3C"GM)
MTKR[S<YV\E5CB_?HH?[7M\R7TV 52)T>DMZ+MV= ?"!V 1$F 6@+1EIG[>SB
M8MW"?+/[BJWM;+YBPZ,&ZW6;_>[Z"@]?'@]#\&I# : O$+$V!,\!L6'QT.E7
M\+#3ZC2[O59[?86)+XX)C&F E$IA"G172GQ<7>4\T6GM,)!-:6!6\/]:\/<S
MYY:#;BAQ<'!6X&"SM>V04/+%5JOGKC5/#]=1]7,6V?&*,<8J#-6TF24X<J=$
M)5O#>-!,I!;K' R)<0:2$91>IL%.7?':E\?U)9E]%J&EYT*.1=4/ P2IW-Y'
MX\X&;=!9F*)_9;T)M/6^ ZM_.6J&\(2,LZKI;,-/$H,>/EA&Q OPET=/3A!.
M&1!T[I<6O%(X<2, TA@\QSQFDC^'H:GAX?'AY=71X+AY<7$R/ ;88W"&C.G^
M5J^[L],OC&F8$ATY/>4S:] 5B:4\=+H/B+M. W#X)@$^06@ZH "3B[;N7QVL
MTWX6G.O:]AKH4Q-&,6>%T; KS;WKVEB4Q-()^(@VL%NY]V,&A ;@N;/!A ,"
MPCP@=![0?X:!%&,;@P?LG:$!C3&9TDYOS(?I*P&;9[+I>^,U=O5 (Z'@?A&L
M\6\P!D62 JG!A2_ST-9<%-,*\QL59O@7+*$(*Z"X*0.YH;S!"4CT[-NP341
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M1JL2 ]\83E_\XQ(/W??J,TRKG/XJI_]SY_1_'2E_!O\)TBA\^_]02P,$%
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M>B8)XIFXVVR>N*:6BTM3Q=<7F5X0FM._?6C.2N5EN<6WPZ*D.[M+;(^&8>:
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M<F]A<'!R;W9A+FAT;5!+ 0(4 Q0    (  *!KUR=C.5*&Q$  *.*   1
M          "  ?T9  !B9VYE+3(P,C8P-3$S+FAT;5!+ 0(4 Q0    (  *!
MKUQHB:H)7P(  /8&   1              "  4<K  !B9VYE+3(P,C8P-3$S
M+GAS9%!+ 0(4 Q0    (  *!KUR$J/OP-0D  "E4   5              "
M =4M  !B9VYE+3(P,C8P-3$S7VQA8BYX;6Q02P$"% ,4    "  "@:]<027Y
M2M<%  #$,   %0              @ $]-P  8F=N92TR,#(V,#4Q,U]P<F4N
9>&UL4$L%!@     %  4 4 $  $<]      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>bgne-20260513_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bgne-20260513.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
        </entity>
        <period>
            <startDate>2026-05-13</startDate>
            <endDate>2026-05-13</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
        </entity>
        <period>
            <startDate>2026-04-14</startDate>
            <endDate>2026-04-14</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001651308</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2026-05-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">BEONE MEDICINES LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">V8</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37686</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">98-1209416</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">Aeschengraben 27</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Basel</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-9">4051</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c-1" id="f-10">CH</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c-1" id="f-11">61</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-2" id="f-12">685 19 00</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">ONC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
